Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Viswanath Arutla
Conception, Synthesis, and Characterization of a Rofecoxib-Combretastatin Hybrid Drug With Potent Cyclooxygenase-2 (COX-2) Inhibiting and Microtubule Disrupting Activities in Colon Cancer Cell Culture and Xenograft Models
Oncotarget
Oncology
Related publications
Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Archives of Internal Medicine
Cytotoxic of Ganoderma Lucidum in Colon Cancer Through Cyclooxygenase 2 (COX-2) as Its Molecular Target
Journal of Tropical Life Science
Reduction in Cancer Risk by Selective and Nonselective Cyclooxygenase-2 (COX-2) Inhibitors
Journal of Experimental Pharmacology
Molecular Medicine
Pharmacology
PROGNOSTIC SIGNIFICANCE OF Ki67, CYCLOOXYGENASE-2 (COX-2) AND P16ink4a IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER
Siberian Journal of Oncology
Cancer Research
Oncology
MiR-26a and miR-144 Inhibit Proliferation and Metastasis of Esophageal Squamous Cell Cancer by Inhibiting Cyclooxygenase-2
Oncotarget
Oncology
The Flavouring Phytochemical 2-Pentanone Reduces Prostaglandin Production and COX-2 Expression in Colon Cancer Cells
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Evaluation of [11C]rofecoxib as PET Tracer for Cyclooxygenase 2 Overexpression in Rat Models of Inflammation
Nuclear Medicine and Biology
Cancer Research
Nuclear Medicine
Radiology
Molecular Medicine
Imaging
Antiangiogenic Activity of the Selective Cyclooxygenase 2 Inhibitor Rofecoxib in Human Colorectal Cancer Liver Metastases
Gut
Gastroenterology
Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
